Alkaloid

Worldwide Isopropyl Alcohol Industry to 2027 - Featuring Exxon Mobil, Shell Chemicals Europe and INEOS Enterprises Group Among Others - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, Juni 9, 2022
Chemicals, Plastics, Manufacturing, Chloroform, Income, Vitamin, Paint, Printing, Ether, Growth, Creosote, COVID-19, Glycerol, Wax, Cellulose, Alcohol, C3H7OH, Industry, Water, Alkaloid, Fats, Acetone, Petrochemical

Although miscible with water, few alcohols, ether and chloroform, isopropyl alcohol is insoluble in salt solutions.

Key Points: 
  • Although miscible with water, few alcohols, ether and chloroform, isopropyl alcohol is insoluble in salt solutions.
  • Isopropyl alcohol is also used in the production of glycerol, shellacs, quick drying inks, isopropyl acetate and creosote.
  • Isopropyl alcohol finds diverse applications in several downstream industries like paint and coating, automotive, cosmetic, printing, pharmaceutical, etc.
  • What is the breakup of the global isopropyl alcohol market based on the industry?

Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT

Retrieved on: 
Dienstag, März 22, 2022
General Health, Pharmaceutical, Health, Other Health, MSD, Hospital, Risk, Pimozide, Abstract, Alkaloid, Viremia, MD Anderson Cancer Center, Plasma, MRK, EBMT, Myopathy, Rhabdomyolysis, Record, Simvastatin, Observation, POR, PubMed, Ergotism, Cytomegalovirus, NYSE, Embase, Mortality, Adult, CMV, HSCT, Publication, Patient, Medicine, Food, Nausea, Drug, Center, IV, Infection, Ciclosporin, Drug interaction, Graft-versus-host disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Society for Primary Immunodeficiencies, Merck & Co., Blood, Tachycardia, Atrial fibrillation, Enzyme, CYP3A, Meta-analysis, University, Disease, Midazolam, Pharmaceutical industry, Airline, Fertilizer, Coffee, Merck, PREVYMIS (LETERMOVIR), CMV AND TREATMENT, MERCK

Consistent results were observed at 200 days of follow-up with respect to CMV reactivation, clinically significant CMV infection, and CMV disease.

Key Points: 
  • Consistent results were observed at 200 days of follow-up with respect to CMV reactivation, clinically significant CMV infection, and CMV disease.
  • CMV infection is a common clinically significant complication in these patients and early CMV reactivation after alloHCT is associated with increased mortality.
  • We are encouraged that the findings from this comprehensive literature review and meta-analysis of real-world observational studies reinforce the effectiveness of PREVYMIS in these patients at risk for CMV infection and disease.
  • The objective of the analysis was to assess the effectiveness of primary prophylaxis with PREVYMIS among adults undergoing alloHCT using systematic literature review and meta-analysis of data from real-world observational studies.

BioBetter Breaks Bottleneck in Cultivated Meat with Tobacco Plants

Retrieved on: 
Dienstag, März 29, 2022
Cell, Method, Alkaloid, The Good Food Institute, Nutrient, Degenerative disease, Fermentation, Bioreactor, GF, Organic acid, Transferrin, Growth, CO2, Adalimumab, Bacteria, Nicotiana, Doctor of Philosophy, Meat, Tobacco smoking, Nicotiana tabacum, CEO, Israel Innovation Authority, Industry, Technology, Protein, A-DNA, MBA, Insulin, Institution, Hebrew University of Jerusalem, Efficiency, Food, Livestock, Agriculture, Fine chemical, MD, GFS

Working behind the scenes of the emerging cultured meat industry, BioBetter is repurposing tobacco plants to create the growth factors necessary for the cellular development of cultivated meat.

Key Points: 
  • Working behind the scenes of the emerging cultured meat industry, BioBetter is repurposing tobacco plants to create the growth factors necessary for the cellular development of cultivated meat.
  • This landmark botanical breakthrough could significantly reduce the cost of cultivated meat and advance it rapidly to scale-up.
  • BioBetter harnessed the inherent advantages of tobacco plants by turning them into bioreactors for expression and large-scale production of the proteins.
  • The company currently sources tobacco plants from local growers but the goal is to eventually source theraw material from tobacco growers globally.

Global Marine Biotechnology Market to Reach $5 Billion by 2026

Retrieved on: 
Montag, März 21, 2022
Risk, CAGR, Nitrogen, BASF SE, Biofouling, Gesellschaft mit beschränkter Haftung, Forecasting, Research, Environment, Agriculture, Lactone, Chitin, Isolation, Population, Players, Marketing, SE, Chitosan, Biomaterial, Aquaculture, Shellfish, Health, PharmaMar, Food, Acetal, Alkaloid, Genetic engineering, Bio, Therapy, Seaweed, Investment, Fertilizer, Growth, Internet, Intelligence, BASF, Electricity, Administration, Ecosystem, Phenomics, SAN, Adoption, Whale, Biopolymer, Tuna, Quinone, Aether, PCR, Salmon, Food industry, Coral Reefs, Microalgae, Drug discovery, Biomass, Safety, Medication, GIA, COVID-19, Biophysical environment, Pharmaceutical industry, Fine chemical, Peptide, Technology

SAN FRANCISCO, March 21, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Marine Biotechnology - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, March 21, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Marine Biotechnology - Global Market Trajectory & Analytics" .
  • The global bioplastics and biopolymers market is increasingly looking towards new advances made in marine biotechnology to develop completely new class of biodegradable biopolymers.
  • Amid the COVID-19 crisis, the global market for Marine Biotechnology estimated at US$3.7 Billion in the year 2022, is projected to reach a revised size of US$5 Billion by 2026, growing at a CAGR of 5.8% over the analysis period.
  • The U.S. Market is Estimated at $1.1 Billion in 2022, While China is Forecast to Reach $481.8 Million by 2026
    The Marine Biotechnology market in the U.S. is estimated at US$1.1 Billion in the year 2022.

ZANOPRIMA LIFESCIENCES FILES PATENT INFRINGEMENT ACTION AGAINST HANGSEN INTERNATIONAL TO ENFORCE ITS GROUNDBREAKING ENZYMATIC PROCESS FOR SYNTHESIZING (S)-NICOTINE

Retrieved on: 
Donnerstag, März 17, 2022
CGMP, Alkaloid, Nicotine, Patent, Herbal cigarette, Complaint, Death, Multimedia, District court, 1836 U.S. Patent Office fire, Douglas v. U.S. District Court ex rel Talk America, ESG, Tobacco, CEO, Chinese patent medicine, Name, Formaldehyde, Goal, Carcinogen, Movement, FDA, Disease, Fine chemical, Generic drug

WACO, Texas, March 17, 2022 /PRNewswire/ -- Zanoprima Lifesciences Ltd. filed a Complaint for Patent Infringement against Hangsen International Group Ltd. ("Hangsen") in the U.S. District Court in the Western District of Texas, Civil Action No.

Key Points: 
  • WACO, Texas, March 17, 2022 /PRNewswire/ -- Zanoprima Lifesciences Ltd. filed a Complaint for Patent Infringement against Hangsen International Group Ltd. ("Hangsen") in the U.S. District Court in the Western District of Texas, Civil Action No.
  • In its Complaint, Zanoprima Lifesciences alleges that Hangsen has violated its patent entitled "Process for Making (S)-Nicotine," ( U.S. Patent No.
  • 10,913,962 ) ("Zanoprima's Patent") through Hangsen's manufacture and importation into the U.S. market products containing synthetic nicotine that are manufactured using Zanoprima Lifescience's patented and groundbreaking process.
  • Zanoprima's Complaint alleges that, after publication of Zanoprima's Patent, Hangsen filed a Chinese Patent Application describing a process that copied the process invented by Zanoprima.

Emissions Study Reveals Attractive Properties of TAAT™ and Beyond Tobacco™ Compared to Popular Tobacco Cigarettes

Retrieved on: 
Mittwoch, Februar 16, 2022
Smoke, Nicotine, Water, Smoking, Company, TPM, SEDAR, Smokeless tobacco, Nitrosamine, Biomass, Originality, Leadership, Alkaloid, GLOBE, Smell, Ageing, Tobacco industry, Board, Â, University of Idaho, Ammonia, Agriculture, Anabasine, CSE, University, News, Fermentation, Investor relations, Tobacco, Medicinal plants, Menthol

Smoke from TAAT products contains 25% less TPM than mainstream smoke of popular tobacco cigarettes.

Key Points: 
  • Smoke from TAAT products contains 25% less TPM than mainstream smoke of popular tobacco cigarettes.
  • TAAT products have a 15% lower tar level compared to popular tobacco cigarettes.
  • TAAT products do not contain any added ammonia, and as a result its emissions contain 50% less ammonia than popular tobacco cigarettes.
  • TAAT products contain less than 10% of the levels of aromatic amines found in popular tobacco cigarettes.

Party Brands Introduces Party Bars, the World's First Party Enhancement Disposable

Retrieved on: 
Dienstag, Januar 25, 2022
Social media, Research, Juice, Anxiety, Science, Party, Mint, Marketing, Entrepreneurship, Cognition, Telephone, Mesembrine, Music, Nature, GLOBE, Alkaloid, Generic drug, Video game, Retail

HUNTINGTON BEACH, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Party lifestyle brand, Party Brands , announced the launch of Party Bars , the world's first Party Enhancement Disposable, powered by Kanna , which the brand is calling "the new active ingredient."

Key Points: 
  • HUNTINGTON BEACH, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Party lifestyle brand, Party Brands , announced the launch of Party Bars , the world's first Party Enhancement Disposable, powered by Kanna , which the brand is calling "the new active ingredient."
  • Party Bars are available in two signature flavors - Natural and Mint - and feature a pre-heat button, rechargeable battery, and 150-puff count.
  • Direct online consumer purchasing via the brand's online store, PartyBrands.com , is expected to become available by early February 2022.
  • To learn more about Party Bars and the other Party Brand products, visit https://partybrands.com
    For sales and wholesale inquiries, contact Party Brands via email at [email protected] or telephone at (714) 823-3750.

AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia

Retrieved on: 
Montag, November 22, 2021
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Azacitidine, Cytarabine, Ara, Alkaloid, Rareș, Mortality, Food, AML, Acute myeloid leukemia, IND, Blood, Microtubule, Euronext, IPK, Investigational New Drug, Population, Efficacy, PGP, Survival, FDA, Person, Patient, Drug resistance, MPO, Haematopoietic system, PDX, Quatre saisons dans le désordre, Language isolate, Prevalence, Ticker, Laboratory, MDS, Ownership, Hemotoxin, AB, Pharmaceutical industry

Study AB18001 is titled A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia.

Key Points: 
  • Study AB18001 is titled A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia.
  • This dose expansion study aims to determine the schedule for a Phase 2 trial in patients with relapsed/refractory AML and to also provide an early efficacy (response rate) assessment of AB8939.
  • The first indication AB8939 is being developed for is acute myeloid leukemia (AML).
  • Moreover, while azacytidine was associated with strong treatment related hematotoxicity, AB8939 did not induce hematotoxicity throughout its 4-week treatment period.

Clint Winters, Medical Scientist, Announces Patent Filing on CONO1000™, A Novel Conolidine Pain Relief Active Ingredient

Retrieved on: 
Dienstag, November 2, 2021
Risk, Alkaloid, Research, Biotechnology, Morphine, Patent, Conolidine, Chronic pain, Pharmaceutical industry, Medicinal plants, Poultry, Fine chemical, Vaccine

ALPHARETTA, Ga., Nov. 2, 2021 /PRNewswire-PRWeb/ --Winters Biotechnology has announced patent filings for CONO1000, a novel dietary ingredient featuring the conolidine alkaloid formulated for natural pain relief.

Key Points: 
  • ALPHARETTA, Ga., Nov. 2, 2021 /PRNewswire-PRWeb/ --Winters Biotechnology has announced patent filings for CONO1000, a novel dietary ingredient featuring the conolidine alkaloid formulated for natural pain relief.
  • However, Clint Winters and Winters Biotechnology have been studying natural conolidine extractions since 2017 in hopes of developing a novel natural ingredient.
  • "Conolidine has been incredibly intriguing to me since I first read the initial pain relief research.
  • In addition to the CONO1000 patent filing, Mr. Winters has also filed two patents with the conolidine alkaloid natural pain killer and an additional patent in relation to the enhancement of CBD.

Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application

Retrieved on: 
Dienstag, Oktober 5, 2021
Psilocybin, Patent, Permeability, Health, Sale, CSE, Patient, Board, IP, Environment, FRA, Company, Dehydration, Alkaloid, Fungus, Science, Research, FDR, Safety, GLOBE, Director, Medicinal plants, Fine chemical

Optimi has discovered a novel, high yielding extraction technique by combining multiple process steps that collectively increase the total yield of alkaloids retrieved from the mushrooms.

Key Points: 
  • Optimi has discovered a novel, high yielding extraction technique by combining multiple process steps that collectively increase the total yield of alkaloids retrieved from the mushrooms.
  • Optimi's unique extraction technique not only increases overall alkaloid yield, but also protects the active alkaloids from degradation.
  • In keeping with Optimi Healths commitment to sustainability and the environment, the proprietary process protected in the patent filing extensively utilizes green chemistry.
  • Optimi Health CEO Bill Ciprick states, Todays announcement reflects our determination to advance the innovation of all-natural mushroom science.